Literature DB >> 9084057

Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?

C Sánchez1, E Meier.   

Abstract

The behavioral profiles of five clinically used selective serotonin reuptake inhibitors (SSRIs) citalopram, paroxetine, sertraline, fluvoxamine and fluoxetine, have been compared in animal models of antidepressant (mouse forced swim test), anxiolytic (exploration of black and white test box and foot-shock-induced ultrasonic vocalization in the rat) and antiaggressive (isolation-induced aggressive behavior in the mouse) activity. the results are discussed in relation to receptor binding data from the literature. Furthermore, affinities for the sigma 1 and sigma 2 binding sites are presented. Citalopram reversed the immobility induced by forced swimming with a potency similar to that of imipramine. Paroxetine, fluvoxamine and fluoxetine reversed swim-induced immobility less potently and with a maximum of 40-50% reversal. Citalopram produced a mixed anxiogenic-/anxiolytic-like response in rats tested in the two-compartment black and white box. Paroxetine induced an anxiogenic-like response at low doses and the other SSRIs were without major effects. Citalopram and paroxetine inhibited footshock-induced ultrasonic vocalization with high potencies. The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition. Sertraline and fluvoxamine inhibited the vocalization less potently, and fluoxetine induced a weak inhibitory effect corresponding to a maximum of 32%. Sertraline, fluvoxamine and fluoxetine inhibited isolation-induced aggressive behavior, whereas citalopram and paroxetine were inactive. Both 5-HT1 and 5-HT2 receptors are involved, and there was a functional interaction between 5-HT1A and 5-HT2A or 5-HT2C receptors, as ritanserin potentiated the antiaggressive effect of 1,5-HTP as well as that of 8-OH-DPAT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084057     DOI: 10.1007/s002130050181

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

Review 1.  Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.

Authors:  G Debonnel; C de Montigny
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

2.  Action of serotoninmimetics in the behavioral despair test in rats.

Authors:  Z Górka; E Wojtasik; H Kwiatek; J Maj
Journal:  Commun Psychopharmacol       Date:  1979

Review 3.  Role of the serotonergic system in the forced swimming test.

Authors:  F Borsini
Journal:  Neurosci Biobehav Rev       Date:  1995       Impact factor: 8.989

4.  Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats.

Authors:  C. Sánchez
Journal:  Behav Pharmacol       Date:  1993-06       Impact factor: 2.293

5.  The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice.

Authors:  C Sánchez; J Arnt; J Hyttel; E K Moltzen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action.

Authors:  E Mogilnicka; A Czyrak; J Maj
Journal:  Eur J Pharmacol       Date:  1987-06-26       Impact factor: 4.432

Review 7.  Preclinical evidence on the psychotropic profile of fluvoxamine.

Authors:  B Olivier; L Bosch; A van Hest; J van der Heyden; J Mos; G van der Poel; J Schipper; M Tulp
Journal:  Pharmacopsychiatry       Date:  1993-05       Impact factor: 5.788

8.  The effect of tianeptine and sertraline in three animal models of depression.

Authors:  J P Kelly; B E Leonard
Journal:  Neuropharmacology       Date:  1994-08       Impact factor: 5.250

9.  Fluoxetine trial in borderline personality disorder.

Authors:  J R Cornelius; P H Soloff; J M Perel; R F Ulrich
Journal:  Psychopharmacol Bull       Date:  1990

10.  Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo.

Authors:  T S Rao; J A Cler; S J Mick; V M Dilworth; P C Contreras; S Iyengar; P L Wood
Journal:  Neuropharmacology       Date:  1990-12       Impact factor: 5.250

View more
  55 in total

1.  Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.

Authors:  Trynke R de Jong; Tommy Pattij; Jan G Veening; Marcel D Waldinger; Alexander R Cools; Berend Olivier
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

2.  Replacement of homologous mouse DNA sequence with pathogenic 6-base human CREB1 promoter sequence creates murine model of major depressive disorder.

Authors:  George S Zubenko; Hugh B Hughes
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-05-19       Impact factor: 3.568

3.  The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.

Authors:  Liliana P Montezinho; Silke Miller; Niels Plath; Nanna Hovelsø Jensen; Jens-Jakob Karlsson; Louise Witten; Arne Mørk
Journal:  Psychopharmacology (Berl)       Date:  2010-07-30       Impact factor: 4.530

4.  Sigma-1 receptor ligands inhibit catecholamine secretion from adrenal chromaffin cells due to block of nicotinic acetylcholine receptors.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Nolan D Hartley; Kyle J Horning; Kevin P M Currie
Journal:  J Neurochem       Date:  2017-09-19       Impact factor: 5.372

Review 5.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Neural Circuit Motifs in Valence Processing.

Authors:  Kay M Tye
Journal:  Neuron       Date:  2018-10-24       Impact factor: 17.173

7.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

8.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 9.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

10.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.